Edition:
India

Aileron Therapeutics Inc (ALRN.OQ)

ALRN.OQ on NASDAQ Stock Exchange Global Market

0.96USD
13 Sep 2019
Change (% chg)

$-0.00 (-0.52%)
Prev Close
$0.96
Open
$0.96
Day's High
$1.01
Day's Low
$0.93
Volume
98,290
Avg. Vol
60,562
52-wk High
$3.52
52-wk Low
$0.46

Latest Key Developments (Source: Significant Developments)

Aileron Therapeutics Announces Management Change
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS ANNOUNCES MANAGEMENT CHANGE.AILERON THERAPEUTICS INC - DON DOUGHERTY, ITS CURRENT CHIEF FINANCIAL OFFICER, WILL BE LEAVING AILERON EFFECTIVE SEPTEMBER 13, 2019.AILERON THERAPEUTICS INC - DON DOUGHERTY, ITS CURRENT CHIEF FINANCIAL OFFICER, WILL BE LEAVING AILERON EFFECTIVE SEPTEMBER 13.AILERON THERAPEUTICS INC - DON DOUGHERTY, ITS CURRENT CHIEF FINANCIAL OFFICER, WILL BE LEAVING AILERON EFFECTIVE SEPTEMBER 13, 2019.AILERON THERAPEUTICS INC - ALL FINANCIAL RESPONSIBILITIES ARE BEING TRANSITIONED TO RICHARD WANSTALL.  Full Article

Aileron Therapeutics Reports Q2 2019 Results
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.26.Q2 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019 WERE $31.5 MILLION, COMPARED TO $20.7 MILLION AS OF DECEMBER 31, 2018.  Full Article

Aileron Announces FDA Acceptance of IND for ALRN-6924 as a Myelopreservation Agent in Patients with p53-mutant Cancer Treated with Chemotherapy
Thursday, 27 Jun 2019 

June 27 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND FOR ALRN-6924 AS A MYELOPRESERVATION AGENT IN PATIENTS WITH P53-MUTANT CANCER TREATED WITH CHEMOTHERAPY.AILERON THERAPEUTICS INC - COMPANY EXPECTS TO ENROLL UP TO 40 PATIENTS IN PHASE 1B PORTION OF PLANNED PHASE 1B/2 TRIAL FOR ALRN-6924.  Full Article

Aileron Therapeutics Updated Information On Design, Anticipated Timing Of Data From Its Ongoing Alrn-6924 Trials
Thursday, 6 Jun 2019 

June 5 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS - UPDATED INFORMATION ON DESIGN, ANTICIPATED TIMING OF DATA FROM ITS ONGOING, PLANNED CLINICAL ALRN-6924 TRIALS.AILERON THERAPEUTICS INC - CONDUCTING A PHASE 2A CLINICAL TRIAL OF COMBINATION OF ALRN-6924 AND PALBOCICLIB (IBRANCE), MARKETED BY PFIZER.AILERON THERAPEUTICS INC - TO HAVE FINAL DATA FROM ALL 25 PATIENTS IN ALRN-6924 TRIAL IN Q2 OF 2020.AILERON THERAPEUTICS INC - PLANS TO DISCLOSE DATA FROM PHASE 1B PORTION OF MYELOPRESERVATION TRIAL IN Q2 OF 2020.  Full Article

Aileron Therapeutics Reports Q1 Loss Per Share Of $0.49
Thursday, 9 May 2019 

May 8 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES DATA.  Full Article

Aileron Therapeutics Appoints Jeffrey Bailey As Chairman Of Board
Monday, 19 Mar 2018 

March 19 (Reuters) - Aileron Therapeutics Inc ::AILERON THERAPEUTICS APPOINTS JEFFREY A. BAILEY TO ITS BOARD OF DIRECTORS.AILERON THERAPEUTICS INC - ‍APPOINTMENT OF JEFFREY BAILEY AS CHAIRMAN OF ITS BOARD​.AILERON THERAPEUTICS INC - ‍BAILEY REPLACES SCOTT KAPNICK AS CHAIRMAN​.AILERON THERAPEUTICS INC - ‍KAPNICK WILL REMAIN A DIRECTOR​.  Full Article

Aileron Therapeutics posts Q3 loss of $0.45 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Aileron Therapeutics Inc :Aileron therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.45.Q3 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Cash, cash equivalents and investments as of Sept. 30, 2017 were $56.9 million, compared to $20.7 million as of December 31, 2016​.Qtrly ‍non-gaap net loss per share attributable to common stockholders $0.43​.  Full Article